{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:15:47Z","timestamp":1791220547406,"version":"4.1.0"},"reference-count":36,"publisher":"Rockefeller University Press","issue":"9","content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,8,29]]},"abstract":"<jats:p>New anticancer drugs that target oncogenic signaling molecules have greatly improved the treatment of certain cancers. However, resistance to targeted therapeutics is a major clinical problem and the redundancy of oncogenic signaling pathways provides back-up mechanisms that allow cancer cells to escape. For example, the AKT and PIM kinases produce parallel oncogenic signals and share many molecular targets, including activators of cap-dependent translation. Here, we show that PIM kinase expression can affect the clinical outcome of lymphoma chemotherapy. We observe the same in animal lymphoma models. Whereas chemoresistance caused by AKT is readily reversed with rapamycin, PIM-mediated resistance is refractory to mTORC1 inhibition. However, both PIM- and AKT-expressing lymphomas depend on cap-dependent translation, and genetic or pharmacological blockade of the translation initiation complex is highly effective against these tumors. The therapeutic effect of blocking cap-dependent translation is mediated, at least in part, by decreased production of short-lived oncoproteins including c-MYC, Cyclin D1, MCL1, and the PIM1\/2 kinases themselves. Hence, targeting the convergence of oncogenic survival signals on translation initiation is an effective alternative to combinations of kinase inhibitors.<\/jats:p>","DOI":"10.1084\/jem.20110846","type":"journal-article","created":{"date-parts":[[2011,8,23]],"date-time":"2011-08-23T00:20:03Z","timestamp":1314058803000},"page":"1799-1807","update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":110,"title":["Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma"],"prefix":"10.1084","volume":"208","author":[{"given":"Jonathan H.","family":"Schatz","sequence":"first","affiliation":[{"name":"Cancer Biology and Genetics Program 1 , 2 , and 3"},{"name":"Stem Cell Center and Developmental Biology Program 1 , 2 , and 3"},{"name":"Program in Molecular Pharmacology, Sloan-Kettering Institute for Cancer Research, New York, NY 10065 1 , 2 , and 3"},{"name":"Department of Medicine 4 , 5 , and 6"},{"name":"Department of Pathology 4 , 5 , and 6"},{"name":"Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 4 , 5 , and 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Oricchio","sequence":"additional","affiliation":[{"name":"Cancer Biology and Genetics Program 1 , 2 , and 3"},{"name":"Stem Cell Center and Developmental Biology Program 1 , 2 , and 3"},{"name":"Program in Molecular Pharmacology, Sloan-Kettering Institute for Cancer Research, New York, NY 10065 1 , 2 , and 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Wolfe","sequence":"additional","affiliation":[{"name":"Cancer Biology and Genetics Program 1 , 2 , and 3"},{"name":"Stem Cell Center and Developmental Biology Program 1 , 2 , and 3"},{"name":"Program in Molecular Pharmacology, Sloan-Kettering Institute for Cancer Research, New York, NY 10065 1 , 2 , and 3"},{"name":"Weill Cornell Graduate School of Medical Science, New York, NY 10065 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Jiang","sequence":"additional","affiliation":[{"name":"Cancer Biology and Genetics Program 1 , 2 , and 3"},{"name":"Stem Cell Center and Developmental Biology Program 1 , 2 , and 3"},{"name":"Program in Molecular Pharmacology, Sloan-Kettering Institute for Cancer Research, New York, NY 10065 1 , 2 , and 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Linkov","sequence":"additional","affiliation":[{"name":"Department of Medicine 4 , 5 , and 6"},{"name":"Department of Pathology 4 , 5 , and 6"},{"name":"Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 4 , 5 , and 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Maragulia","sequence":"additional","affiliation":[{"name":"Department of Medicine 4 , 5 , and 6"},{"name":"Department of Pathology 4 , 5 , and 6"},{"name":"Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 4 , 5 , and 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiji","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Medicine 4 , 5 , and 6"},{"name":"Department of Pathology 4 , 5 , and 6"},{"name":"Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 4 , 5 , and 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medicine 4 , 5 , and 6"},{"name":"Department of Pathology 4 , 5 , and 6"},{"name":"Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 4 , 5 , and 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinagolu K.","family":"Rajasekhar","sequence":"additional","affiliation":[{"name":"Cancer Biology and Genetics Program 1 , 2 , and 3"},{"name":"Stem Cell Center and Developmental Biology Program 1 , 2 , and 3"},{"name":"Program in Molecular Pharmacology, Sloan-Kettering Institute for Cancer Research, New York, NY 10065 1 , 2 , and 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nen C.","family":"Pagano","sequence":"additional","affiliation":[{"name":"Cancer Biology and Genetics Program 1 , 2 , and 3"},{"name":"Stem Cell Center and Developmental Biology Program 1 , 2 , and 3"},{"name":"Program in Molecular Pharmacology, Sloan-Kettering Institute for Cancer Research, New York, NY 10065 1 , 2 , and 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"John A.","family":"Porco","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Center for Chemical Methodology and Library Development, Boston University, Boston, MA 02215 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Teruya-Feldstein","sequence":"additional","affiliation":[{"name":"Department of Medicine 4 , 5 , and 6"},{"name":"Department of Pathology 4 , 5 , and 6"},{"name":"Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 4 , 5 , and 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Rosen","sequence":"additional","affiliation":[{"name":"Cancer Biology and Genetics Program 1 , 2 , and 3"},{"name":"Stem Cell Center and Developmental Biology Program 1 , 2 , and 3"},{"name":"Program in Molecular Pharmacology, Sloan-Kettering Institute for Cancer Research, New York, NY 10065 1 , 2 , and 3"},{"name":"Department of Medicine 4 , 5 , and 6"},{"name":"Department of Pathology 4 , 5 , and 6"},{"name":"Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 4 , 5 , and 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[{"name":"Department of Medicine 4 , 5 , and 6"},{"name":"Department of Pathology 4 , 5 , and 6"},{"name":"Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 4 , 5 , and 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Pelletier","sequence":"additional","affiliation":[{"name":"Department of Biochemistry 9 and 10"},{"name":"Rosalind and Morris Goodman Cancer Center, McGill University, Montreal, Quebec H3G 1Y6, Canada 9 and 10"},{"name":"Department of Biochemistry 9 and 10"},{"name":"Rosalind and Morris Goodman Cancer Center, McGill University, Montreal, Quebec H3G 1Y6, Canada 9 and 10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Guido","family":"Wendel","sequence":"additional","affiliation":[{"name":"Cancer Biology and Genetics Program 1 , 2 , and 3"},{"name":"Stem Cell Center and Developmental Biology Program 1 , 2 , and 3"},{"name":"Program in Molecular Pharmacology, Sloan-Kettering Institute for Cancer Research, New York, NY 10065 1 , 2 , and 3"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2011,8,22]]},"reference":[{"key":"2023072600464135600_bib1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/318533a0","article-title":"The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice","volume":"318","author":"Adams","year":"1985","journal-title":"Nature."},{"key":"2023072600464135600_bib2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature."},{"key":"2023072600464135600_bib3","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ng1532","article-title":"Reverse engineering of regulatory networks in human B cells","volume":"37","author":"Basso","year":"2005","journal-title":"Nat. Genet."},{"key":"2023072600464135600_bib4","first-page":"2651","article-title":"Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model","volume":"118","author":"Bordeleau","year":"2008","journal-title":"J. Clin. Invest."},{"key":"2023072600464135600_bib5","doi-asserted-by":"publisher","first-page":"e5223","DOI":"10.1371\/journal.pone.0005223","article-title":"Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol","volume":"4","author":"Cencic","year":"2009","journal-title":"PLoS ONE."},{"key":"2023072600464135600_bib6","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1182\/blood-2009-03-212852","article-title":"Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells","volume":"114","author":"Chen","year":"2009","journal-title":"Blood."},{"key":"2023072600464135600_bib7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrclinonc.2010.21","article-title":"mTOR signaling and drug development in cancer","volume":"7","author":"Dancey","year":"2010","journal-title":"Nat Rev Clin Oncol."},{"issue":"Suppl 3","key":"2023072600464135600_bib8","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1053\/j.seminoncol.2009.10.010","article-title":"Evaluating temsirolimus activity in multiple tumors: a review of clinical trials","volume":"36","author":"Dancey","year":"2009","journal-title":"Semin. Oncol."},{"key":"2023072600464135600_bib9","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2003-07-2469","article-title":"VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia","volume":"103","author":"Egle","year":"2004","journal-title":"Blood."},{"key":"2023072600464135600_bib10","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1371\/journal.pbio.1000038","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"Feldman","year":"2009","journal-title":"PLoS Biol."},{"key":"2023072600464135600_bib11","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1101\/gad.1105003","article-title":"The serine\/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor","volume":"17","author":"Fox","year":"2003","journal-title":"Genes Dev."},{"key":"2023072600464135600_bib12","first-page":"iv136","article-title":"PIM inhibition as a rational therapeutic approach in diffuse large B-cell lymphoma","volume":"22","author":"G\u00f3mez-Abad","year":"2011","journal-title":"Ann. Oncol."},{"key":"2023072600464135600_bib13","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1182\/blood-2004-09-3706","article-title":"Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival","volume":"105","author":"Hammerman","year":"2005","journal-title":"Blood."},{"key":"2023072600464135600_bib14","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1053\/hupa.2002.127438","article-title":"Application of tissue microarray technology to the study of non-Hodgkin\u2019s and Hodgkin\u2019s lymphoma","volume":"33","author":"Hedvat","year":"2002","journal-title":"Hum. Pathol."},{"key":"2023072600464135600_bib15","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"2023072600464135600_bib16","first-page":"1371","article-title":"Pim-1 protein expression is regulated by its 5\u2032-untranslated region and translation initiation factor elF-4E","volume":"8","author":"Hoover","year":"1997","journal-title":"Cell Growth Differ."},{"key":"2023072600464135600_bib17","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1080\/10428190802419640","article-title":"Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study","volume":"49","author":"Hsi","year":"2008","journal-title":"Leuk. Lymphoma."},{"key":"2023072600464135600_bib18","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2023072600464135600_bib19","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1101\/gad.1690808","article-title":"Tumorigenic activity and therapeutic inhibition of Rheb GTPase","volume":"22","author":"Mavrakis","year":"2008","journal-title":"Genes Dev."},{"key":"2023072600464135600_bib20","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/ncb2037","article-title":"Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia","volume":"12","author":"Mavrakis","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"2023072600464135600_bib21","doi-asserted-by":"publisher","first-page":"10853","DOI":"10.1073\/pnas.0804821105","article-title":"mTORC1 promotes survival through translational control of Mcl-1","volume":"105","author":"Mills","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072600464135600_bib22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1517\/13543770903496442","article-title":"Pim kinase inhibitors: a survey of the patent literature","volume":"20","author":"Morwick","year":"2010","journal-title":"Expert Opin Ther Pat."},{"key":"2023072600464135600_bib23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrc2986","article-title":"For better or for worse: the role of Pim oncogenes in tumorigenesis","volume":"11","author":"Nawijn","year":"2011","journal-title":"Nat. Rev. Cancer."},{"key":"2023072600464135600_bib24","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res."},{"key":"2023072600464135600_bib25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1600-0609.2005.00429.x","article-title":"Microarray-based classification of diffuse large B-cell lymphoma","volume":"74","author":"Poulsen","year":"2005","journal-title":"Eur. J. Haematol."},{"key":"2023072600464135600_bib26","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1261\/rna.950608","article-title":"Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs","volume":"14","author":"Rong","year":"2008","journal-title":"RNA."},{"key":"2023072600464135600_bib27","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J. Exp. Med."},{"key":"2023072600464135600_bib28","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/449993a","article-title":"Cancer: mixing cocktails","volume":"449","author":"Sawyers","year":"2007","journal-title":"Nature."},{"key":"2023072600464135600_bib29","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","article-title":"Temsirolimus has activity in non-mantle cell non-Hodgkin\u2019s lymphoma subtypes: The University of Chicago phase II consortium","volume":"28","author":"Smith","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"2023072600464135600_bib30","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.cell.2009.01.042","article-title":"Regulation of translation initiation in eukaryotes: mechanisms and biological targets","volume":"136","author":"Sonenberg","year":"2009","journal-title":"Cell."},{"key":"2023072600464135600_bib31","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","article-title":"Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb","volume":"13","author":"Tee","year":"2003","journal-title":"Curr. Biol."},{"key":"2023072600464135600_bib32","doi-asserted-by":"publisher","first-page":"8023","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1","volume":"284","author":"Thoreen","year":"2009","journal-title":"J. Biol. Chem."},{"key":"2023072600464135600_bib33","first-page":"1176","article-title":"Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally","volume":"11","author":"Verbeek","year":"1991","journal-title":"Mol. Cell. Biol."},{"key":"2023072600464135600_bib34","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nature02369","article-title":"Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy","volume":"428","author":"Wendel","year":"2004","journal-title":"Nature."},{"key":"2023072600464135600_bib35","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1101\/gad.1604407","article-title":"Dissecting eIF4E action in tumorigenesis","volume":"21","author":"Wendel","year":"2007","journal-title":"Genes Dev."},{"key":"2023072600464135600_bib36","doi-asserted-by":"publisher","first-page":"9991","DOI":"10.1073\/pnas.1732008100","article-title":"A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma","volume":"100","author":"Wright","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA."}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/208\/9\/1799\/1742976\/jem_20110846.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/208\/9\/1799\/1742976\/jem_20110846.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:47:12Z","timestamp":1690332432000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/208\/9\/1799\/41034\/Targeting-cap-dependent-translation-blocks"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,22]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,8,29]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20110846","relation":{},"ISSN":["1540-9538","0022-1007"],"issn-type":[{"value":"1540-9538","type":"electronic"},{"value":"0022-1007","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8,22]]}}}